Sysmex (6869) Stock Overview
Engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
6869 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sysmex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,859.50 |
| 52 Week High | JP¥2,012.50 |
| 52 Week Low | JP¥1,246.00 |
| Beta | 0.71 |
| 1 Month Change | -2.00% |
| 3 Month Change | 36.33% |
| 1 Year Change | -0.24% |
| 3 Year Change | -24.87% |
| 5 Year Change | -62.62% |
| Change since IPO | 1,759.50% |
Recent News & Updates
6869: Collaboration, Guidance And Completed Buyback Will Support A Steady Outlook
Analysts have raised their price target for Sysmex from ¥1,800 to about ¥2,060. They cited updated assumptions for revenue growth, profit margin and future P/E levels as key drivers of the change.
6869: Share Buybacks And Upgraded Earnings Guidance Will Support Stronger Returns
Analysts now place Sysmex's fair value at ¥2,967, up from ¥2,747, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E, which together indicate a modestly higher valuation framework. What’s in the News for Sysmex Sysmex raised its consolidated earnings guidance for the six months ending September 30, 2026 and for the full year ending March 31, 2027, citing stronger hematology instrument sales in the Americas and a weaker yen than previously assumed.Recent updates
6869: Collaboration, Guidance And Completed Buyback Will Support A Steady Outlook
Analysts have raised their price target for Sysmex from ¥1,800 to about ¥2,060. They cited updated assumptions for revenue growth, profit margin and future P/E levels as key drivers of the change.6869: Share Buybacks And Upgraded Earnings Guidance Will Support Stronger Returns
Analysts now place Sysmex's fair value at ¥2,967, up from ¥2,747, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E, which together indicate a modestly higher valuation framework. What’s in the News for Sysmex Sysmex raised its consolidated earnings guidance for the six months ending September 30, 2026 and for the full year ending March 31, 2027, citing stronger hematology instrument sales in the Americas and a weaker yen than previously assumed.6869: Earnings Upgrade And Buyback Will Support A Steady Outlook
Analysts have lifted their price target on Sysmex to ¥1,800 from ¥1,732.67, citing updated assumptions around slightly higher profit margins and a lower projected future P/E multiple that together reshape their valuation view. What’s in the News for Sysmex Sysmex raised consolidated earnings guidance for the six months ending September 30, 2026, now projecting net sales of ¥265,000 million, operating profit of ¥25,000 million and profit attributable to owners of the parent of ¥15,000 million or ¥24.68 per basic share, compared with previous guidance of net sales of ¥255,000 million, operating profit of ¥23,000 million and profit attributable to owners of the parent of ¥14,000 million or ¥22.53 per basic share.6869: Share Buybacks And New Collaboration Will Support Stronger Returns
Analysts have raised their price target on Sysmex from ¥2,655 to ¥2,747, citing updated assumptions for revenue growth, profit margins, and a slightly lower discount rate that influence their valuation and P/E expectations. What’s in the News for Sysmex Sysmex completed a share buyback program announced on March 5, 2026, repurchasing a total of 21,138,200 shares, representing 3.41% of shares, for ¥29,999.88 million as of July 17, 2026.
Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings
Catalysts About Sysmex Sysmex is a global diagnostics company focused on hematology, hemostasis, urinalysis and related testing systems for clinical laboratories and hospitals. What are the underlying business or industry changes driving this perspective?Sysmex (TSE:6869) Stock Could Be 17.8% Undervalued After VolitionRx Collaboration
Collaboration news puts Sysmex stock in focus Sysmex (TSE:6869) is back on investors' radar after VolitionRx Limited announced a collaboration to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform, targeting diseases linked to NETosis. See our latest analysis for Sysmex. At a share price of ¥1,424.5, Sysmex has seen modest positive share price momentum in the past month with a 1-month share price return of 3.11% and 90-day share price return of 2.85%, yet the 1-year total shareholder...Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects
Catalysts About Sysmex Sysmex is a diagnostics company focused on hematology, hemostasis, urinalysis and clinical chemistry systems and reagents for hospitals and laboratories worldwide. What are the underlying business or industry changes driving this perspective?Aging Demographics And Global Expansion Will Drive Long Term Diagnostic Demand
Catalysts About Sysmex Sysmex is a global diagnostics company focused on hematology, hemostasis, urinalysis and clinical chemistry systems and reagents for hospitals and laboratories. What are the underlying business or industry changes driving this perspective?Sysmex's (TSE:6869) Soft Earnings Are Actually Better Than They Appear
Soft earnings didn't appear to concern Sysmex Corporation's ( TSE:6869 ) shareholders over the last week. Our analysis...Sysmex Corporation (TSE:6869) Annual Results: Here's What Analysts Are Forecasting For This Year
Last week saw the newest yearly earnings release from Sysmex Corporation ( TSE:6869 ), an important milestone in the...Sysmex Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
There's been a notable change in appetite for Sysmex Corporation ( TSE:6869 ) shares in the week since its quarterly...Sysmex (TSE:6869) Is Due To Pay A Dividend Of ¥19.00
Sysmex Corporation ( TSE:6869 ) has announced that it will pay a dividend of ¥19.00 per share on the 30th of June. This...Estimating The Intrinsic Value Of Sysmex Corporation (TSE:6869)
Key Insights The projected fair value for Sysmex is JP¥1,737 based on 2 Stage Free Cash Flow to Equity With JP¥1,492...Sysmex Corporation's (TSE:6869) Share Price Matching Investor Opinion
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 14x, you may consider Sysmex...These 4 Measures Indicate That Sysmex (TSE:6869) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Sysmex (TSE:6869) Will Pay A Dividend Of ¥19.00
Sysmex Corporation's ( TSE:6869 ) investors are due to receive a payment of ¥19.00 per share on 30th of June. This will...Earnings Miss: Sysmex Corporation Missed EPS By 6.2% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Sysmex Corporation ( TSE:6869 ) released its half-year result to the market. The...Returns On Capital At Sysmex (TSE:6869) Have Stalled
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Shareholder Returns
| 6869 | JP Medical Equipment | JP Market | |
|---|---|---|---|
| 7D | 4.1% | 1.1% | 0.6% |
| 1Y | -0.2% | 5.0% | 28.6% |
Return vs Industry: 6869 underperformed the JP Medical Equipment industry which returned 5% over the past year.
Return vs Market: 6869 underperformed the JP Market which returned 28.6% over the past year.
Price Volatility
| 6869 volatility | |
|---|---|
| 6869 Average Weekly Movement | 7.4% |
| Medical Equipment Industry Average Movement | 3.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 8.6% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 6869's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 6869's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 10,861 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business.
Sysmex Corporation Fundamentals Summary
| 6869 fundamental statistics | |
|---|---|
| Market cap | JP¥1.13t |
| Earnings (TTM) | JP¥39.60b |
| Revenue (TTM) | JP¥524.95b |
Is 6869 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6869 income statement (TTM) | |
|---|---|
| Revenue | JP¥524.95b |
| Cost of Revenue | JP¥257.42b |
| Gross Profit | JP¥267.53b |
| Other Expenses | JP¥227.93b |
| Earnings | JP¥39.60b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 10, 2026
| Earnings per share (EPS) | 65.42 |
| Gross Margin | 50.96% |
| Net Profit Margin | 7.54% |
| Debt/Equity Ratio | 16.8% |
How did 6869 perform over the long term?
See historical performance and comparisonDividends
Does 6869 pay a reliable dividends?
See 6869 dividend history and benchmarks| Sysmex dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2026 |
| Dividend Pay Date | Dec 02 2026 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 74 days |
Does 6869 pay a reliable dividends?
See 6869 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 01:54 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sysmex Corporation is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masahiro Nakanomyo | Barclays |
| Kei Takeuchi | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |